Once cancer has been treated in a patient to the point where remission can be declared, the issue then faced by the patient and their cancer care team is preventing the cancer from returning. This is the stage where adjuvant therapies are considered and incorporated into the patient’s cancer care. Adjuvant therapies aren’t new, however continual research into the field is identifying novel therapies, and new ways to combine existing therapies to optimize patient outcomes and prevent cancer recurrence.
There are a wide variety of adjuvant therapies available, ranging from chemotherapy and radiotherapy, to hormone therapy and cell targeted therapy. There is no cure-all treatment when it comes to cancer, and preventing recurrence brings with it the same hurdles for cancer care teams to maneuver, including unsavory side effects, expensive treatment courses, and difficult to procure medications and supplements. This leaves prescribers with the difficult task of weighing up the risks of therapies with the potential benefit to patients and their cancer care, therefore the more research into adjuvant therapies, the stronger the basis of these rationales will be with a strong foundation of emerging research.
This research topic aims to bring together research from the world of oncology relating to refining existing or identifying novel adjuvant therapies used in cancer treatment, or new combinations of adjuvant therapies. It also aims to highlight methods of improving palatability of existing therapies which will impact patients benefit of life while undergoing these therapies.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Novel therapeutic agents used as adjuvant therapy
- New combinations of adjuvant therapies
- Repurposing medications for use as cancer adjuvant therapy
- Using supplements to optimize adjuvant therapy outcomes
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Once cancer has been treated in a patient to the point where remission can be declared, the issue then faced by the patient and their cancer care team is preventing the cancer from returning. This is the stage where adjuvant therapies are considered and incorporated into the patient’s cancer care. Adjuvant therapies aren’t new, however continual research into the field is identifying novel therapies, and new ways to combine existing therapies to optimize patient outcomes and prevent cancer recurrence.
There are a wide variety of adjuvant therapies available, ranging from chemotherapy and radiotherapy, to hormone therapy and cell targeted therapy. There is no cure-all treatment when it comes to cancer, and preventing recurrence brings with it the same hurdles for cancer care teams to maneuver, including unsavory side effects, expensive treatment courses, and difficult to procure medications and supplements. This leaves prescribers with the difficult task of weighing up the risks of therapies with the potential benefit to patients and their cancer care, therefore the more research into adjuvant therapies, the stronger the basis of these rationales will be with a strong foundation of emerging research.
This research topic aims to bring together research from the world of oncology relating to refining existing or identifying novel adjuvant therapies used in cancer treatment, or new combinations of adjuvant therapies. It also aims to highlight methods of improving palatability of existing therapies which will impact patients benefit of life while undergoing these therapies.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Novel therapeutic agents used as adjuvant therapy
- New combinations of adjuvant therapies
- Repurposing medications for use as cancer adjuvant therapy
- Using supplements to optimize adjuvant therapy outcomes
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
